1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Transdermal Drug Delivery System Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases and need for effective drug delivery
5.1.1.2. Surging adoption of third generation transdermal drug delivery system
5.1.2. Restraints
5.1.2.1. Concerns associated with irritation or skin sensitivity over patch usage
5.1.3. Opportunities
5.1.3.1. Ongoing research & development in transdermal drug delivery system
5.1.3.2. Inorganic growth strategies between pharmaceutical companies and TDDS vendors
5.1.4. Challenges
5.1.4.1. Probable risk of drug failure through transdermal systems and product recalls
5.2. Market Segmentation Analysis
5.2.1. Type: Significant penetration of transdermal patches over traditional drugs
5.2.2. Application: Expanding use in transdermal estrogen therapy
5.2.3. End User: Extensive potential for deployment in home care settings
5.3. Market Trend Analysis
5.3.1. Potential power of market players and surge in regulatory approvals in the American region
5.3.2. Surging healthcare spendings and inclusion of overseas players in the APAC region
5.3.3. Persistent research activities and the growing burden of chronic disease in the EMEA region.
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Transdermal Drug Delivery System Market, by Type
6.1. Introduction
6.2. Transdermal Patches
6.3.1. Drug-In-Adhesive Patches
6.3.2. Matrix Patches
6.3.3. Microneedle Patches
6.3.4. Reservoir Membrane Patches
6.3. Transdermal Semisolids
6.4.1. Gels
6.4.2. Ointments
6.4.3. Sprays
7. Transdermal Drug Delivery System Market, by Application
7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Central Nervous System Disorders
7.4. Hormonal Applications
7.5. Pain Management
7.6. Transdermal Estrogen Therapy
8. Transdermal Drug Delivery System Market, by End User
8.1. Introduction
8.2. Home Care Settings
8.3. Hospitals & Clinics
9. Americas Transdermal Drug Delivery System Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Transdermal Drug Delivery System Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Transdermal Drug Delivery System Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. LTS Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business
12.3.1.2. DifGen Pharmaceuticals Acquires Aveva Drug Delivery Services Inc.
12.3.1.3. Kindeva merges with Meridian to create global CDMO specializing in drug-device combinations
12.3.1.4. Love Pharma Moves To Buy Transdermal Opioid-Use Disorder Player
12.3.1.5. Lowenstein Represents Pharma Tech LTS Lohmann Therapy Systems, Corp. in Acquisition of Tapemark Inc.
12.3.2. New Product Launch & Enhancement
12.3.2.1. Corium Launches ADLARITY (donepezil transdermal system) for Patients with Alzheimer’s Dementia
12.3.3. Investment & Funding
12.3.3.1. LTS Lohmann leads investment in needle-free delivery specialist
12.3.4. Award, Recognition, & Expansion
12.3.4.1. Zydus Lifesciences gets final approval from the U.S. FDA to market Estradiol Transdermal System
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. 3M Company
13.1.2. AdhexPharma, SAS
13.1.3. Bayers AG
13.1.4. Biotts Inc.
13.1.5. Boehringer Ingelheim International GmbH
13.1.6. DuPont de Nemours, Inc.
13.1.7. Gensco Pharma
13.1.8. Hisamitsu Pharmaceutical Co., Inc.
13.1.9. IBSA Farmaceutici Italia Srl
13.1.10. IntelGenx Corp.
13.1.11. Johnson & Johnson Services, Inc.
13.1.12. Kindeva Drug Delivery L.P.
13.1.13. Lavipharm S.A.
13.1.14. Lead Chemical Co., Ltd.
13.1.15. Luye Life Sciences Group
13.1.16. Medherant Limited
13.1.17. Nitto Denko Corporation
13.1.18. Novartis International AG
13.1.19. Nutriband Inc.
13.1.20. Purdue Pharma L.P.
13.1.21. Sorrento Therapeutics, Inc.
13.1.22. Sparsha Pharma International Pvt. Ltd.
13.1.23. Starton Therapeutics
13.1.24. Toa Eiyo Ltd.
13.1.25. Toyo Ink SC Holdings Co., Ltd.
13.1.26. Transdermal Therapeutics, Inc.
13.1.27. UCB S.A.
13.1.28. Viatris Inc.
13.1.29. Zhongshan Senwell Bio Technology Co., Ltd.
13.1.30. Zynerba Pharmaceuticals, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing